Esperion Therapeutics Inc (ESPR)
2.08
+0.02
(+0.97%)
USD |
NASDAQ |
May 03, 16:00
2.08
0.00 (0.00%)
After-Hours: 20:00
Esperion Therapeutics Accounts Receivable (Quarterly): 48.49M for Dec. 31, 2023
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 48.49M |
| September 30, 2023 | 42.62M |
| June 30, 2023 | 40.80M |
| March 31, 2023 | 36.42M |
| December 31, 2022 | 33.73M |
| September 30, 2022 | 31.49M |
| June 30, 2022 | 27.84M |
| Date | Value |
|---|---|
| March 31, 2022 | 25.12M |
| December 31, 2021 | 22.93M |
| September 30, 2021 | 21.71M |
| June 30, 2021 | 21.85M |
| March 31, 2021 | |
| December 31, 2020 | 12.39M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
12.39M
Minimum
Dec 2020
48.49M
Maximum
Dec 2023
30.45M
Average
29.67M
Median
Accounts Receivable (Quarterly) Benchmarks
| United Therapeutics Corp | 307.30M |
| Dynavax Technologies Corp | 40.61M |
| Heron Therapeutics Inc | 60.14M |
| Aldeyra Therapeutics Inc | -- |
| Deciphera Pharmaceuticals Inc | 31.95M |